This CME program from the Cleveland Clinic Journal of Medicine explores a patient with a history of major depressive disorder, progressively worsening altered mental status, intermittent blank staring, blurred vision, bilateral incoordination of the upper and lower extremities, difficulty following commands, and decreased verbal communication. Would you rule out stroke? Serotonin syndrome? Earn some credits while discovering the diagnosis.

A dermatologist describes alopecic and aseptic nodules (AANS) of the scalp, a new clinical entity that has likely escaped many diagnoses. Here is a primer on the condition and how you can ensure a proper diagnosis to alleviate patients’ anxiety, as most have a good prognosis with straightforward therapeutic maneuvers.

Dry cough, fever, and shortness of breath are common symptoms of COVID-19. As a dermatologist, you should also know that the coronavirus can also affect your patients’ skin and toes and may, in fact, be the only symptom. Here is what to look for — complete with images — in patients that test positive for COVID-19 and how you can best treat.

The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate cancer patients.

Research from Johns Hopkins Kimmel Cancer Center showed that combination therapy of cabozantinib and nivolumab could make curative surgery possible for some liver cancer patients who would normally not be considered for such a procedure. Among 15 people with hepatocellular carcinoma (HCC) in the study who could not be treated previously with surgery, the drugs allowed 12 patients to undergo successful surgical removal of their cancer. Five of these 12 patients had only 10% or less of their tumor remaining after the drug treatment.

In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.